BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36960997)

  • 1. Characterizing the Bone Marrow Environment in Advanced-Stage Myelofibrosis during Ruxolitinib Treatment Using PET/CT and MRI: A Pilot Study.
    Slot S; Lavini C; Zwezerijnen GJC; Boden BJH; Marcus JT; Huisman MC; Yaqub M; Barbé E; Wondergem MJ; Zijlstra JM; Zweegman S; Raijmakers PG
    Tomography; 2023 Feb; 9(2):459-474. PubMed ID: 36960997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The value of bone marrow, liver, and spleen imaging in diagnosis, prognostication, and follow-up monitoring of myeloproliferative neoplasms: a systematic review.
    Slot S; van de Donk NWCJ; Otten RHJ; Boden BJH; Zijlstra J; Raijmakers PGHM; Zweegman S
    Cancer Imaging; 2021 Apr; 21(1):36. PubMed ID: 33879266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Importance of Bone Marrow Uptake on Baseline
    Soydal C; Koksoy EB; Yasar A; Turgal E; Erdogan BD; Akbulut H; Kucuk NO
    Cancer Biother Radiopharm; 2016 Dec; 31(10):361-365. PubMed ID: 27996313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing Bone Marrow Activity in Patients with Myelofibrosis: Results of a Pilot Study of
    Vercellino L; Ouvrier MJ; Barré E; Cassinat B; de Beco V; Dosquet C; Chevret S; Meignin V; Chomienne C; Toubert ME; Merlet P; Kiladjian JJ
    J Nucl Med; 2017 Oct; 58(10):1603-1608. PubMed ID: 28360204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Informativeness of whole-body diffusion-weighted magnetic resonance imaging and positron emission tomography with computed tomography in follicular lymphoma].
    Nesterova ES; Yatsyk GA; Lutsik NS; Kravchenko SK; Sudarikov AB; Krasil'nikova IV; Gemdzhian EG; Kovrigina AM
    Ter Arkh; 2020 Sep; 92(7):55-62. PubMed ID: 33346445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole-body MRI, FDG-PET/CT, and bone marrow biopsy, for the assessment of bone marrow involvement in patients with newly diagnosed lymphoma.
    Albano D; Patti C; Lagalla R; Midiri M; Galia M
    J Magn Reson Imaging; 2017 Apr; 45(4):1082-1089. PubMed ID: 27603267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for brain metastases in patients with stage III non-small-cell lung cancer, magnetic resonance imaging or computed tomography? A prospective study.
    Schoenmaekers J; Hofman P; Bootsma G; Westenend M; de Booij M; Schreurs W; Houben R; De Ruysscher D; Dingemans AM; Hendriks LEL
    Eur J Cancer; 2019 Jul; 115():88-96. PubMed ID: 31129385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of
    Lee JW; Choi JS; Lyu J; Lee SM
    Lung Cancer; 2018 Apr; 118():41-47. PubMed ID: 29572001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Significance of FDG Uptake of Bone Marrow on PET/CT in Patients With Non-Small-Cell Lung Cancer After Curative Surgical Resection.
    Lee JW; Na JO; Kang DY; Lee SY; Lee SM
    Clin Lung Cancer; 2017 Mar; 18(2):198-206. PubMed ID: 27495385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ¹⁸F-FDG PET/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders.
    Dammacco F; Rubini G; Ferrari C; Vacca A; Racanelli V
    Clin Exp Med; 2015 Feb; 15(1):1-18. PubMed ID: 25218739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone marrow abnormalities and early bone lesions in multiple myeloma and its precursor disease: a prospective study using functional and morphologic imaging.
    Bhutani M; Turkbey B; Tan E; Korde N; Kwok M; Manasanch EE; Tageja N; Mailankody S; Roschewski M; Mulquin M; Carpenter A; Lamping E; Minter AR; Weiss BM; Mena E; Lindenberg L; Calvo KR; Maric I; Usmani SZ; Choyke PL; Kurdziel K; Landgren O
    Leuk Lymphoma; 2016 May; 57(5):1114-21. PubMed ID: 26690712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole-body MRI with diffusion-weighted imaging: a valuable alternative to contrast-enhanced CT for initial staging of aggressive lymphoma.
    Balbo-Mussetto A; Cirillo S; Bruna R; Gueli A; Saviolo C; Petracchini M; Fornari A; Lario CV; Gottardi D; De Crescenzo A; Tarella C
    Clin Radiol; 2016 Mar; 71(3):271-9. PubMed ID: 26749081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognostic value of bone marrow (18)F-FDG uptake pattern of pretreatment PET-CT in extranodal NK/T cell lymphoma].
    Zhang Y; Zhou J; Wang L; Li JY; Ding CY
    Zhonghua Zhong Liu Za Zhi; 2020 Oct; 42(10):885-890. PubMed ID: 33113633
    [No Abstract]   [Full Text] [Related]  

  • 15. PET/CT predicts bone marrow involvement in paediatric non-Hodgkin lymphoma and may preclude the need for bone marrow biopsy in selected patients.
    Chen S; Wang S; He K; Ma C; Fu H; Wang H
    Eur Radiol; 2018 Jul; 28(7):2942-2950. PubMed ID: 29383519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastric cancer and image-derived quantitative parameters: Part 2-a critical review of DCE-MRI and
    Tang L; Wang XJ; Baba H; Giganti F
    Eur Radiol; 2020 Jan; 30(1):247-260. PubMed ID: 31392480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
    Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A
    J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positron emission tomography - computed tomography as a monitoring response tool in pre-fibrotic myelofibrosis: A case report.
    Qamar Uz Zaman A; Hussain S; Zaheer R; Andleeb M; Raza S; Siddiqui T
    J Pak Med Assoc; 2022 Mar; 72(3):564-566. PubMed ID: 35320247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative MRI reveals heterogeneous impacts of treatment on diseased bone marrow in a mouse model of myelofibrosis.
    Robison TH; Lee W; Luker KE; Pettit K; Talpaz M; Chenevert TL; Ross BD; Luker GD
    Magn Reson Med; 2024 Jun; 91(6):2568-2578. PubMed ID: 38265182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions.
    Eiber M; Takei T; Souvatzoglou M; Mayerhoefer ME; Fürst S; Gaertner FC; Loeffelbein DJ; Rummeny EJ; Ziegler SI; Schwaiger M; Beer AJ
    J Nucl Med; 2014 Feb; 55(2):191-7. PubMed ID: 24309383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.